Precision Medicine

The explosion of genetic and molecular medicine has produced mountains of options and evidence. Conversely, there is often an alarming lack of evidence. This is where we come in.

We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:

  • Will testing change patient management for this indication?
  • If so, what tests and/or therapies should I use?
  • Should we cover testing and/or therapies?
  • Can we manage these services internally?

 

 

AlloSure Kidney (CareDx Inc.)

This report evaluates the AlloSure Kidney test for acute and chronic kidney transplant rejection (antibody-mediated and/or T-cell mediated) in patients for either surveillance or for-cause evaluation.

Nodify XL2 (Biodesix Inc.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify XL2 test.

CHARGE Syndrome

This report reviews clinical study abstracts and clinical practice guidelines addressing genetic testing for the familial form of CHARGE syndrome.

Nodify CDT (Biodesix Inc.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify CDT test.

Prospera (Natera Inc.)

This report evaluates the analytical validity, clinical validity, and clinical utility of the Prospera test.

Clinical Utility of Whole Genome Sequencing (WGS) and Whole Exome Sequencing (WES) in Patients with Intellectual Disability (ID)

This report evaluates the clinical utility of whole genome sequencing (WGS) and whole exome sequencing (WES) in patients with a primary phenotype of intellectual disability (ID). In general, ID may be associated with other neurological disorders, various genetic syndromes, and autism spectrum disorders. However, this report focuses on patients whose primary phenotype of conce…

VeriStrat for Prognostic Use in Patients with Advanced NSCLC (Biodesix Inc.)

The report evaluates the analytical validity, clinical validity, and clinical utility of the VeriStrat test, a liquid biopsy-based proteomic test that identifies a chronic inflammatory immune response indicative of aggressive disease in patients with advanced non-small cell lung cancer (NSCLC) and is intended to provide prognostic information to assist physicians with patient…